Search Within

Isabelle C Riviere

  1. "Maria Palomba"
  2. "Brigitte Senechal"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (3)
Groups
  1. Adult Leukemia (11)
  2. Center for Hematologic Malignancies (11)
  3. Department of Medicine (11)
  4. GSK Faculty (11)
  5. Hematologic Malignancies Research (11)
  6. Hematologic Malignancies, Division of (11)

More Groups

People
  1. Brigitte Senechal (11)
  2. Jae Park (11)
  3. Maria Palomba (11)
  4. Xiuyan Wang (11)
  5. Michel Sadelain (10)
  6. Renier Brentjens (7)

More People

Years
  1. 2023 (3)
  2. 2022 (3)
  3. 2020 (1)
  4. 2019 (2)
  5. 2018 (2)
Publications
  1. Blood (4)
  2. Hematological Oncology (2)
  3. Clinical Lymphoma, Myeloma and Leukemia (1)
  4. Clinical Pharmacology & Therapeutics (1)
  5. JCI Insight (1)
  6. Journal for ImmunoTherapy of Cancer (1)

More Publications

Publishers
  1. American Society of Hematology (4)
  2. Wiley Blackwell (2)
  3. Amer Soc Clinical Investigation Inc (1)
  4. Biomed Central Ltd (1)
  5. Elsevier Inc. (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Validation of a high-sensitivity assay for detection of chimeric antigen receptor T-cell vectors using low-partition digital PCR technology
    Journal Article

    Arcila, M. E.; Patel, U.; Momeni-Boroujeni, A.; Yao, J.; Chan, R.; Chan, J.; Rijo, I.; Yu, W.; Chaves, N.; Patel, H.; more...
    Journal of Molecular Diagnostics (2023)

    Fulltext@MSK | Save
  • Characterizing the relationship between cellular kinetics and response to support dosing recommendations for Cd19-targeted 19(T2)28z1xx cell therapy
    Meeting Abstract

    Li, J.; Singh, R.; Dey, A.; Sellner, L.; Liu, R.; Dash, A.; Park, J.; Palomba, M.; Mansilla-Soto, J.; Senechal, B.; more...
    Clinical Pharmacology & Therapeutics (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19‐targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Palomba, M. L.; Riviere, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E. R.; Liotta, K.; Li, J.; Sellner, L.; Sadelain, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: A preclinical model and initial clinical experience
    Journal Article

    Palomba, M. L.; Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Rivière, I.; Sadelain, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Journal Article

    Geyer, M. B.; Riviere, I.; Senechal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Palomba, M. L.; Halton, E.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save
  • A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
    Blood (2018)

    Fulltext@MSK | Save